CD276, also known as (B7-H3) , is a type I transmembrane protein. The extracellular region contains two pairs of the same immunoglobulin variable and constant regions. The intracellular region is very short and has no clear signal motif. Its mRNA level expression is relatively extensive, but protein expression is relatively limited to non-immune cells such as resting fibroblasts, endothelial cells, osteoblasts, amniotic fluid stem cells, and induced antigen-presenting cells and NK cells. Many studies have revealed that B7-H3 is overexpressed in a variety of tumors, including melanoma, leukemia, breast cancer, prostate cancer, colorectal cancer and other tumors. The expression level is closely related to the poor prognosis and clinical outcome of patients. Participated in immune evasion of tumors. Although its molecular mechanism is still unclear, as a possible immune checkpoint molecule, it is a promising target for tumor immunotherapy. This product is a CD276-FC recombinant protein (the FC tag can be removed by enterokinase) , which can be used for monoclonal antibody screening or antibody function verification.

Product name: Recombinant human C276 protein

Species: Human origin

Gene sequence number: Q5ZPR3

Tags: Human-Fc Tag

Tag site: C terminal

Restriction site: enterokinase

Expression area: extracellular segment (29-534AA)

Host cell: CHO

Purity: ＞90%

Purification method: Protein A column

Preservation system: PBS+20% glycerol

Storage conditions: -80℃

Illustration:: Lane M on the left is the protein MW marker, Lane 1 is 15ug CD276(29-534)-Fc protein;

The image on the right shows the 293T binding of CD276-FC protein and overexpressed CD276-CAR detected by FACS

Reference materials:

1. B7-H3: A Costimulatory Molecule for T Cell Activation and IFN-gamma Production

2. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

3. B7-H3 Promotes Acute and Chronic Allograft Rejection